PTPN2 Antibodies

Tyrosine-protein phosphatase non-receptor type 2 (PTPN2)

Non-receptor type tyrosine-specific phosphatase which dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR. Additionally dephosphorylates non-receptor protein tyrosine kinases like JAK1, JAK2, JAK3, Src family kinases, STAT1, STAT3 and STAT6 either in the nucleus or the cytoplasm.

Plays a multifaceted and important role in the maturation of the immune system. Functions in T-cell receptor signaling through dephosphorylation of FYN and LCK to control T-cells differentiation and activation.

Gene Information

Human
Gene Name:	PTPN2
Uniprot:	P17706
Entrez:	5771

Family

Belongs to:
protein-tyrosine phosphatase family

Alternative Names

protein tyrosine phosphatase, non-receptor type 2; PTP2; PTPN2; PTPTPTN2; T-cell protein tyrosine phosphatase; T-cell protein-tyrosine phosphatase; TCELLPTP; TCPTP; TC-PTP; TCPTPEC 3.1.3.48; tyrosine-protein phosphatase non-receptor type 2

Molecular Weight

Mass (kDA):
48.473 kDA

Genomic Context

Human
Location:	18p11.21
Sequence:	18; NC_000018.10 (12785478..12884351, complement)

Tissue Specificity

Ubiquitously expressed. Isoform 2 is probably the major isoform. Isoform 1 is expressed in T-cells and in placenta.

Subcellular Localizations

[Isoform 1]: Endoplasmic reticulum. Endoplasmic reticulum-Golgi intermediate compartment. Targeted to the endoplasmic reticulum by its C-terminal hydrophobic region.; [Isoform 2]: Nucleus. Cytoplasm. Cell membrane. Predominantly localizes to chromatin (By similarity). Able to shuttle between the nucleus and the cytoplasm and to dephosphorylate plasma membrane receptors (PubMed:9488479). Recruited by activated ITGA1 at the plasma membrane.

Diseases

• Crohn Disease
• Diabetes Mellitus
• Diabetes Mellitus, Insulin-dependent
• Posttransfusion Purpura
• Autoimmune Reaction
• Autoimmune Diseases
• Colitis
• Ulcer
• Rheumatoid Arthritis
• Arthritis
• Ulcerative Colitis
• Autoimmunity
• Neoplasms

• Inflammatory Bowel Diseases
• Leukemia
• Malignant Neoplasms
• Diabetes Mellitus, Non-insulin-dependent
• Inflammation
• Intestinal Diseases
• Lymphoma

Interacting Proteins

• GHR
• TMED10
• TMED9

Pathways

• Pathogenesis
• Immune Response
• Secretion
• Cell Proliferation
• Cell Cycle
• Localization
• Autophagy
• Hyperphosphorylation
• Cell Adhesion
• Cytokine Secretion
• Rna Interference
• Gluconeogenesis
• Glucose Homeostasis

• S Phase
• Lymphocyte Activation
• Chemotaxis
• T Cell Proliferation
• Nuclear Import
• Cell Development
• Cell Death

PTMs

• Phosphorylation
• Dephosphorylation

• Oxidation
• Methylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/PTPN2

Boster Bio Anti-PTN2 - Best Uses Of The PTPN2 Marker

This article explains the benefits of Boster bio Anti-PTN2 PTPN2 marker and how scientists may use it to improve their research. It also discusses the clinical applications of PTPN2 marker and its safety and quality. All scientists around the globe can benefit from the information provided. We hope that you find it useful. This article is meant to help you decide if Boster Bio Anti PTPN2 suits you.

Boster Bio Anti-PTN2 PPN2 Marker

Boster Bio Anti–PTN2 peptide mark is a monoclonal antibody. It has been tested in ELISA as well as Western Blotting. It has been validated on Mouse and Rat as well as Human. It is safe for diagnostic and research use. The BosterBio Anti -PTN2 Peptide marker is reasonably priced. Its catalog number is A08233.

Clinical applications

A new study has identified a potential therapeutic target for atherosclerosis by assessing PTPN2 levels in patients. This marker is a potent inhibitor for macrophage inflammation. To determine the therapeutic potential, clinical trials are currently underway. This study has important implications for atherosclerosis research. This study shows that PTPN2 antibody can inhibit macrophage inflammation.

The study also identified genes that are involved in the IFNg signaling pathway. Interestingly, genes involved in the IFNg pathway were also enriched. These genes include PD-1, CD47, JAK1 (and STAT1) genes. These findings suggest that PTPN2 inhibitors may improve the effectiveness of immunotherapy regimens for cancer. While further research is required to determine the function of PTPN2, these findings are very exciting.

Two isoforms of the PTPN2 gene exist. One is found within the endoplasmic-reticulum, while another is found in and around the nucleus. The PTPN2 gene is thought to be a tumour suppressor. Nonetheless, breast cancer has not been studied extensively using this marker. To assess the protein expression in breast cancer tissues, immunohistochemistry has been used. Droplet digital PCR has also been used.

The intestinal barrier can only be maintained by the PTPN2 protein gene. In mice lacking PTPN2, the intestinal barrier can be compromised, leading to inflammatory disorders. Mice with PTPN2 gene mutations also show an increase in permeability, and TEER. The effects of mutant macrophages were reversed by anti-IL6 antibodies. Although the PTPN2 genetic mutation is still poorly understood, it will soon be demonstrated that it can improve patient care.

PTPN2 expression was closely linked to immune responses among glioma victims. It was also found to be negatively associated with MGMT promoter methylation and IDh2 mutation. Patients with glioma who had higher PTPN2 expression had shorter OS. These results suggest that tumor heterogeneity may affect the prognosis in glioma.

In the mouse model, PTPN2-deficient mice had increased T-cell expansion and lymphocytic infiltrates in non-lymphoid tissues. Moreover serum levels of PTPN2 were correlated with the level immunosuppressive lymphocytes, including Tregs and MDSCs. Future research is needed to identify the exact interactions between PTPN2 genes and immunosuppressive cell.

Safety

PAAD's promising therapeutic target is the PTPN2 protein biomarker. It has been shown to be associated with PAAD-related inflammation as well as immune checkpoint signaling. It has been proven to improve PAAD patient survival. However, safety concerns are still prevalent. However, studies are required in order to validate its role for PAAD treatment. The PTPN2 biomarker was developed. Its clinical utility will be discussed below.

PTPN2 can be regulated by the STAT1-EGFR genes. It is thought to be involved in the progression of PAAD. Silencing PTPN2 causes STAT1 & EGFR expression to be inhibited. To confirm its safety GSVA has been performed. Here, it was shown that PTPN2 expression levels are associated with IgG levels.

The PTPN2 genes is expressed in cancer tissues. It is associated with immune reactions. PTPN2 expression has been associated with a shorter OS in both the TCGA-CGGA cohorts. However, researchers have also investigated PTPN2 levels in GBM. This is due to tumor heterogeneity. GBM patients with high PTPN2 levels had a worse outcome.

Using databases of glioma tumors, the PTPN2 gene expression was investigated. PTPN2 levels were higher in glioblastomas compared to the CGGA population. Interestingly, IDH mutations are a strong determinant of glioma grade. Tumors are more vulnerable to immunotherapy if PTPN2 is absent.

PTPN2 is a biomarker that iTregs cells are present. TCR regulates PTPN2’s expression. TCR signals activate FOXO1, so knocking down PTPN2 can reverse the process and restore FOXO1. ACD3 can also be an important factor in immunotherapy.

Quality

The PTPN2 marker is a protein found in the cell membrane. It is an important marker for many biological processes, including research into cancer and the development of new medicines. Boster Bio antibodies have a high affinity and are frequently cited by scientists. They are a trusted choice in the research community and have been validated by Western Blotting, Immunohistochemistry, and ELISA.